Stable lipid microparticle solution of palmitoylethanolamide for appetite control
A novel solvent-free, stable lipid microparticle solution of palmitoylethanolamide (PEA) designed for rapid appetite regulation. This technology offers a liquid alternative to traditional capsules, enhancing bioavailability and effectiveness as a functional beverage or sublingual spray.
Overview
This innovative solution features a stable lipid microparticle formulation of palmitoylethanolamide (PEA), a compound known for reducing chronic pain and inflammation. The new formulation enhances bioavailability and offers a fast-acting, neutral-taste option for appetite regulation. By targeting signaling receptors involved in lipogenesis and appetite control, this product can help reduce food intake and support weight management. It is designed for development as a functional beverage or as an effective sublingual spray.
Technical specifications
- Solvent-free, stable lipid microparticle formulation: Enhances bioavailability and offers rapid action compared to traditional PEA capsules.
- Neutral taste: Facilitates incorporation into beverages or use as a sublingual spray.
- Mechanism of action: Involves activation of PPAR-alfa and other receptors (GPR55, GPR119, CB1, CB2, TRPV1) to inhibit lipogenesis and reduce appetite.
- Potential applications: Functional ingredient in beverages or as a fast-acting sublingual spray for appetite control.
Technology readiness level
The technology is currently at TRL 4, with existing formulations ready for clinical testing. Future validation involves a placebo-controlled, double-blind, randomized trial to confirm efficacy and safety, alongside product development for beverage application.
About Eyesiu Medicines BV
Eyesiu Medicines BV, founded in 2014 and based at the Leiden Bio Science Park in the Netherlands, specializes in the development of innovative therapeutics and nutraceuticals. The company leverages advanced nanotechnology, specifically proprietary PEGylated lipid nanoparticle delivery technology, to improve the efficacy and delivery of existing therapeutics and body-own molecules. This technology allows for the creation of solvent-free, stable formulations that can be administered via various routes, including intranasal, ocular, dermal, and inhalation, targeting inflammatory processes across neurology, ophthalmology, dermatology, and pulmonology. The company differentiates its approach by using this platform to enhance the performance of established compounds for broader clinical applications.
These advancements are significant for addressing chronic inflammatory disorders and improving patient quality of life. By optimizing the delivery of molecules like cyclosporine A and palmitoylethanolamide (PEA), Eyesiu aims to provide more effective treatments for conditions affecting the brain, eyes, lungs, skin, and hair. In addition to its preclinical pharmaceutical pipeline, the company operates a consumer healthcare division, Eyesiu Care, which offers nutraceutical products like the PEArlboost+ spray. Eyesiu continues to expand its intellectual property portfolio through international patent grants for its lipid particle formulas and actively explores product partnerships to further its research and development initiatives.
Inquire about this partnering listing
Industry applications
delivered to your inbox.